News | December 21, 2012

Early Results Show Fewer Treatments, Higher Doses of Proton Therapy for Prostate Cancer Well Tolerated

Shorter course of treatment more convenient, cost-effective for patients

For men undergoing proton therapy for prostate cancer, fewer treatments with higher doses appear to be well tolerated, according to early clinical trial results. The trial, which continues to enroll patients, is evaluating using only 5 proton treatments given over 2 weeks for patients with low risk prostate cancer, a fraction of the 44 treatments typical in an 8-week standard course of therapy.

Patients who underwent the short-course of treatment reported no change in pre-treatment gastrointestinal, genitourinary or sexual function 6 months after completing therapy; no change in hormonal status was noted. The study reported on the outcomes of the first 22 who have completed treatment; more than 45 patients have now been enrolled on the protocol.

“This early analysis shows that short-course treatment is well tolerated, a result we continue to see in additional patients who we have enrolled in the trial and who have completed their therapy,” said Dr. William Hartsell, medical director of the CDH Proton Center, A ProCure Center, in Warrenville, Ill. “Being able to successfully treat patients in just a fraction of the time is not only convenient for patients, it also translates into substantial cost reductions.”

The study, which is led by Dr. Hartsell, is being conducted in the suburban Chicago center as well as the ProCure Proton Therapy Center in Oklahoma City. Ten patients were treated over 1 to 2 weeks at a higher dose for 5 treatments; another 12 patients were treated over 8 to 9 weeks with a standard proton dose and 44-day course of treatment. Prior to undergoing treatment and every 3 months following, side effects were monitored using industry-standard, patient-reported outcome measurements.

Data on the trial were presented at the Radiological Society of North America (RSNA) 98th Scientific Assembly and Annual Meeting.

Proton therapy for prostate cancer is clinically proven to be beneficial. Earlier this year, four studies, including one from ProCure, presented at the American Society for Radiation Oncology (ASTRO) annual meeting showed that proton therapy successfully reduces treatment related side effects and helps maintain a high quality of life for men with prostate cancer. The studies found little to no decline in genitourinary and gastrointestinal function for men treated with proton therapy and a faster return to pre-treatment function compared to standard X-ray radiation therapy.

“The body of research showing the benefits of proton therapy for prostate cancer is growing,” Hartsell said. “There is evidence that proton therapy results in fewer side effects compared to standard X-ray radiation therapy. With more research into shorter courses of treatment, we will continue to see the cost of the treatment come down while still maintaining the same quality of life patients have come to expect.”

For more information: www.procure.com/il

Related Content

Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
FDA Clears GammaPod Stereotactic Radiotherapy System for Breast Cancer Treatment
Technology | Stereotactic Body Radiation Therapy (SBRT) | December 22, 2017
The U.S. Food and Drug Administration (FDA) has cleared the new GammaPod noninvasive stereotactic radiotherapy system...
RaySearch Launches RayCare Oncology Information System

Image courtesy of RaySearch Laboratories

Technology | Oncology Information Management Systems (OIMS) | December 22, 2017
RaySearch announced the first release of RayCare, a new oncology information system (OIS) designed to connect the...
RaySearch Releases RayStation 7 Radiotherapy Treatment Planning System
Technology | Treatment Planning | December 19, 2017
RayStation 7, the latest release of RaySearch’s radiation therapy treatment planning system, adds new functionality and...
Overlay Init